Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Maintains Target Price $6.2

Moomoo NewsDec 5 12:31 ET · Ratings

Atea Pharmaceuticals Hold Rating: Promising Phase 2 Outcomes Amidst Clinical and Market Challenges

TipRanksDec 5 12:18 ET · Ratings

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

BenzingaDec 4 15:14 ET

Express News | Atea Pharmaceuticals Inc: Global Phase 3 Program Initiation Expected Early in 2025

ReutersDec 4 08:20 ET

Express News | Atea Pharmaceuticals Announced That The Company's Phase 2 Study Of The Regimen Of Bemnifosbuvir, A Nucleotide Analog Polymerase Inhibitor, And Ruzasvir, An Ns5a Inhibitor, For Treatment Of Hepatitis C Virus Met Its Primary Endpoints Of Safety And...

BenzingaDec 4 07:02 ET

Express News | Atea Pharmaceuticals Inc - Phase 2 Study Achieves 98% Svr12 After 8 Weeks

ReutersDec 4 07:01 ET